Spring Bank Pharmaceuticals
A clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform.
Launch date
Employees
Market cap
-
Enterprise valuation
€42—63m (Dealroom.co estimates Jan 2015.)
Milford Connecticut (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$3.9m | Grant | ||
| N/A | $4.2m | Debt | |
| N/A | $6.3m | Debt | |
| N/A | $11.6m | Early VC | |
| N/A | N/A | IPO | |
N/A | Merger | ||
| Total Funding | €14.1m | ||
Related Content
Recent News about Spring Bank Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Spring Bank Pharmaceuticals
Edit
ACQUISITION by invoX Pharma Jun 2022